Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Abou-Alfa Highlights HCC Advances, Unmet Needs in Other GI Cancers

Brandon Scalea
Published: Wednesday, Jan 16, 2019

Dr Ghassan Abou-Alfa

Ghassan Abou-Alfa, MD
While the hepatocellular carcinoma (HCC) field shifted in 2018 with the addition of newly available treatment options, more pivotal research is on the way, said Ghassan K. Abou-Alfa, MD.

, Abou-Alfa, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed the rapidly evolving treatment options in HCC and other developments in GI cancers.

OncLive: What have been the biggest advancements made in the field of HCC?

Abou-Alfa: It has been a great year with regard to many malignancies. Specifically, in the hepatobiliary domain, we have seen many positive changes. We are going to continue hearing a lot about the advances [being made] in HCC.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication